中华眼底病杂志

中华眼底病杂志

康柏西普玻璃体腔注射治疗早产儿视网膜病变的疗效观察及其影响因素分析

查看全文

目的观察并探讨玻璃体腔注射康柏西普治疗早产儿视网膜病变(ROP)的疗效和影响因素。方法回顾性病例研究。2017年10月至2018年6月在河南省人民医院新生儿重症监护室和眼科筛查确诊为阈值前期1型、阈值期和急进型后极部ROP(AP-ROP)患儿57例57只眼纳入研究。其中,阈值前期1型30例30只眼,阈值期21例21只眼,AP-ROP 6例6只眼。所有患儿在确诊后24 h内常规玻璃体腔注射10.00 mg/ml的康柏西普0.025 ml(含康柏西普0.25 mg)。注射后7 d内行眼底检查,其后根据眼底情况决定检查间隔时间为1~3周/次。随访时间≥24周,平均随访时间(30.1±4.6)周。病情复发或治疗无反应者,给予重复玻璃体腔注射康柏西普或激光光凝治疗。随访观察患眼视网膜血管变化情况。疗效多因素相关性检验采用logistic逐步回归分析。结果57只眼中,行1、2次玻璃体注射康柏西普治疗分别为49、8只眼。治疗后24周,57只眼中,治愈26只眼(45.6%),好转22只眼(38.6%),复发8只眼(14.0%),加重1只眼(1.8%)。复发时间为首次治疗后(12.9±4.5)周,矫正胎龄(49.0±6.7)周。治愈、好转与复发患眼之间首次注射时间(F=5.124)、病变范围(F=7.122)比较,差异有统计学意义(P<0.01、<0.01);治愈、好转、复发患眼之间不同ROP类型、病变分区和分期、有无附加病变比较,差异均有统计学意义(χ2=11.784、14.100、6.896、9.935,P<0.01、<0.01、<0.05、<0.01)。Logistic逐步回归分析结果显示,Ⅰ区病变较Ⅱ区病变更易复发(Wald值=9.879,OR=27.333,P=0.002)。所有患眼治疗中和随访过程中后均未出现眼内炎、白内障、青光眼等与注射相关的并发症。结论玻璃体腔注射康柏西普治疗ROP有效,无明显不良反应;病变分区与治疗后复发相关。

ObjectiveTo observe the effect of intravitreal injection of conbercept in the treatment of retinopathy of premature (ROP) and to analyze the factors related to the therapy.MethodsA retrospective study. A total of 57 patients (57 eyes) with pre-threshold type 1 (30 patients, 30 eyes), threshold ROP (21 patients, 21 eyes) and acute aggressive posterior ROP (APROP, 6 patients, 6 eyes)) from premature infants by retinal screening in Henan Provincial People’s Hospital during October 2017 and June 2018 were enrolled in this study. All children were received routinely intravitreal injected 10 mg/ml conbercept 0.025 ml (0.25 mg) within 24 hours after diagnosis. Fundus examination was performed 7 days after injection. The interval of examination was 1−3 weeks according to fundus conditions. The mean follow-up was 30.1±4.6 weeks. For patients with relapse or no response to treatment, repeated intravitreal injection of conbercept or laser photocoagulation therapy was given. The retinal blood vessels of the affected eyes were observed. Logistic stepwise regression analysis was used for the correlation test of multiple factors.ResultsAmong 57 eyes, 49 eyes and 8 eyes were treated with 1 or 2 times of intravitreal injection of conbercept. After 24 weeks of treatment, in 57 eyes, 26 eyes were cured (45.6%), 22 eyes improved (38.6%), 8 eyes relapsed (14.0%), and 1 eye aggravated (1.8%). The recurrence time was 12.9±4.5 weeks after the first injection, and the corrected gestational age was 49.0±6.7 weeks. There were significant differences in initial injection time, lesion range among the cure, improved and recurrence eyes (F=5.124, 7.122; P<0.01, <0.01). Parameters of ROP condition, including ROP diagnosis (pre-threshold type 1, threshold and APROP), zone (zone 1 and 2), stage (stage 2 and 3) and plus lesions, were significant different among the cure, improved and recurrence eyes (χ2=11.784, 14.100, 6.896, 9.935; P<0.01, <0.01, <0.05, <0.01). Logistic stepwise regression analysis showed that the recurrence rate was correlated with ROP zone, more likely recurrence at zone 1 than zone 2 (Wald=9.879, OR=27.333, P=0.002). No injection-related complications such as endophthalmitis, cataract and glaucoma were found during treatment and follow-up period.ConclusionsIntravitreal injection of conbercept is effective in the treatment of ROP without obvious adverse reactions. Lesion zoning is associated with recurrence after treatment.

关键词: 早产儿视网膜病/药物疗法; 血管生成抑制剂/治疗应用; 抗体,单克隆/治疗应用; 影响因素分析

Key words: Retinopathy of prematurity/drug therapy; Angiogenesis inhibitors/therapeutic use; Antibodies, monoclonal/therapeutic use; Root cause analysis

引用本文: 张海涛, 万素华, 靳玮, 徐英英. 康柏西普玻璃体腔注射治疗早产儿视网膜病变的疗效观察及其影响因素分析. 中华眼底病杂志, 2019, 35(2): 171-175. doi: 10.3760/cma.j.issn.1005-1015.2019.02.012 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. Geisen P, Peterson LJ, Mariniuk D, et al. Neutralizing antibody to VEGF reduces intravitreous neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity[J]. Mol Vis, 2008, 14(11): 345-357.
2. Wang H, Yang Z, Jiang Y, et al. Quantitative analyses of retinal vascular area and density after different methods to reduce VEGF in a rat model of retinopathy of prematurity[J]. Invest Ophthalmol Vis Sci, 2014, 55(2): 737-744. DOI: 10.1167/iovs.13-13429.
3. Mintz-Hittner HA, Kennedy KA, Chuang AZ, et al. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity[J]. N Engl J Med, 2011, 364(7): 603-615. DOI: 10.1056/NEJMoa1007374.
4. Mintz-Hittner HA. Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors[J]. Early Hum Dev, 2012, 88(12): 937-941. DOI: 10.1016/j.earlhumdev.2012.09.019.
5. Wu WC, Kuo HK, Yeh PT, et al. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan[J]. Am J Ophthalmol, 2013, 155(1): 150-158. DOI: 10.1016/j.ajo.2012.06.010.
6. Nicoară SD, Nascutzy C, Cristian C, et al. Outcomes and prognostic factors of intravitreal bevacizumab monotherapy in zone Ⅰ stage 3+ and aggressive posterior retinopathy of prematurity[J/OL]. J Ophthalmol, 2015, 2015: 102582[2015-09-27]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600496/. DOI: 10.1155/2015/102582.
7. Karkhaneh R, Khodabande A, Riazi-Eafahani M, et al. Efficacy of intravitreal bevacizumab for zone-Ⅱretinopathy of prematurity[J]. Acta Ophthalmol, 2016, 94(6): 417-420. DOI: 10.1111/aos.13008.
8. VanderVeen DK, Melia M, Yang MB, et al. Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity:a report by the American Academy of Ophthalmology[J]. Ophthalmology, 2017, 124(5): 619-633. DOI: 10.1016/j.ophtha.2016.12.025.
9. Huang Q, Zhang Q, Fei P, et al. Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: anatomic outcomes and influencing factors[J]. Ophthalmology, 2017, 124(8): 1156-1164. DOI: 10.1016/j.ophtha.2017.03.018.
10. Bai Y, Nie H, Wei S, et al. Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity[J/OL]. Br J Ophthalmol, 2018, 2018: E1[2018-07-20]. http://dx.doi.org/10.1136/bjophthalmol-2017-311662. DOI: 10.1136/bjophthalmol-2017-311662. [published online ahead of print].
11. Jin E, Yin H, Li X, et al. Short-term outcomes after intravitreal injections of conbercept versus ranibizumab for the treatment of retinopathy of prematurity[J]. Retina, 2018, 38(8): 1595-1604. DOI: 10.1097/IAE.0000000000001763.
12. 程湧, 梁建宏, 黎晓新. 康柏西普玻璃体腔注射治疗急进性后极部早产儿视网膜病变的疗效观察[J]. 中华眼底病杂志, 2017, 33(2): 144-147. DOI: 10.3760/cma.j.issn.1005-1015.2017.02.008.Cheng Y, Liang JH, Li XX. Intravitreal injection of conbercept for aggressive posterior retinopathy of prematurity[J]. Chin J Ocul Fundus Dis, 2017, 33(2): 144-147. DOI: 10.3760/cma.j.issn.1005-1015.2017.02.008.
13. International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited[J]. Arch Ophthalmol, 2005, 123(7): 991-999. DOI: 10.1001/archopht.123.7.991.
14. Moran S, O’Keefe M, Hartnett C, et al. Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity[J]. Acta Ophthalmol, 2014, 92(6): 496-497. DOI: 10.1111/aos.12339.
15. Gunay M, Sukgen EA, Celik G, et al. Comparison of Bevacizumab,Ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey[J]. Curr Eye Res, 2017, 42(3): 462-429. DOI: 10.1080/02713683.2016.1196709.
16. Mueller B, Salchow DJ, Waffenschmidt E, et al. Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone[J]. Br J Ophthalmol, 2017, 101(3): 365-370. DOI: 10.1136/bjophthalmol-2016-308375.
17. Hu Q, Bai Y, Chen X, et al. Recurrence of retinopathy of prematurity in zone Ⅱ stage 3+ after Ranibizumab Treatment: a retrospective study[J/OL]. J Ophthalmol, 2017, 2017: 5078565 [2017-04-09]. https://doi.org/10.1155/2017/5078565. DOI: 10.1155/2017/5078565.
18. Mintz-Hittner HA, Geloneck MM, Chuang AZ. Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy[J]. Ophthalmology, 2016, 123(9): 1845-1855. DOI: 10.1016/j.ophtha.2016.04.028.
19. Klaassen I, van Geest RJ, Kuiper EJ, et al. The role of CTGF in diabetic retinopathy[J]. Exp Eye Res, 2015, 133: 37-48. DOI: 10.1016/j.exer.2014.10.016.
20. Hartnett ME. Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity[J]. Clin Perinatol, 2014, 41(4): 925-943. DOI: 10.1016/j.clp.2014.08.011.
21. Harder BC, von Baltz S, Jonas JB, et al. Intravitreal low-dosage bevacizumab for retinopathy of prematurity[J]. Acta Ophthalmol, 2014, 92(6): 577-581. DOI: 10.1111/aos.12266.
22. Cheng Y, Meng Q, Linghu D, et al. A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity[J]. Sci Rep, 2018, 8(1): 10732. DOI: 10.1038/s41598-018-28987-6.